The drug, Avigan, is made by Fujifilm. It’s a decades-old flu treatment in Japan, but health officials have repeatedly rejected the use of the drug in the U.S.
The White House National Security Council reportedly has been pushing for the U.S. to accept donations of the drug from Japan, which would require the FDA to grant emergency use authorization for Avigan to be used against COVID-19, according to Politico.
Fujifilm, the FDA and HHS also have discussed clinical trials of Avigan in the U.S., according to documents reviewed by Politico.
Japanese Prime Minister Shinzo Abe has championed the drug for use in combating COVID-19 and Japan is conducting clinical trials testing its effectiveness against the disease, reports Politico. Fujifilm has also asked the U.S. to fund its research on the drug.
Chinese scientists have also championed the drug, Politico reported. But U.S. researchers have expressed concern about risks associated with it, including birth defects, and have said the drug data from China is insufficient.
An FDA spokesperson told Politico that the agency “will not speculate” on whether the agency will grant an emergency use authorization for the drug.
Read the full article here.
More articles on pharmacy:
How 5 hospital pharmacies have responded to the coronavirus pandemic
CARES Act doesn’t do enough to expand pharmacist roles, ASHP says
FDA issues emergency use authorization for hydroxychloroquine and chloroquine to treat COVID-19
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
